Fig. 5: Tumor remission and duration of response. | Nature Communications

Fig. 5: Tumor remission and duration of response.

From: Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial

Fig. 5

a Best percentage change in target lesion size from baseline. According to the RECIST 1.1 criteria, ORR was 21.4% (95% CI: 13.3–29.4%) and DCR was 63.1% (95% CI: 53.6–72.6%). b Kaplan–Meier curves for the DoR. The patients who achieved an objective response had a DoR of 13.0 months (95% CI: 2.5–23.5). The 95% CIs for point estimates are shown in blue shading. Data are presented as median (95% CI). Source data are provided as a Source Data file. ORR objective response rate, DCR disease control rate, DoR duration of response.

Back to article page